Asset 2Asset 2Asset 2Asset 2
  • Capabilities
    • Trial Design and Management
    • Data Management
    • Regulatory and Quality
    • Consulting and Program Management
    • Biospecimens and Logistics
  • Expertise
    • Trial Types
    • Health Innovation Solutions
    • Clinical Applications
  • About Us
    • Company
    • Management Team
  • News & Events
  • Contact
✕
            No results See all results
            • Filter by
            • Categories
            • Tags
            • Authors
            • Show all
            • All
            • Events
            • GBC Blog
            • In Vitro Diagnostics - IVD News
            • Press Releases
            • All
            • All
            • neil.mucci@globalbioclinical.com
            May 18, 2020
            Published by admin on May 18, 2020
            Categories
            • GBC Blog

            F.D.A. Clears Everlywell Coronavirus Testing Kit for Use at Home

            The agency granted emergency clearance for a testing kit that allows a consumer to take a nasal sample at home and send it to a laboratory […]
            Do you like it?0
            Read more
            May 18, 2020
            Published by admin on May 18, 2020
            Categories
            • GBC Blog

            Gates-Backed At-Home COVID-19 Testing Program

            (Reuters) – An at-home coronavirus testing project in Seattle backed in part by the Bill and Melinda Gates Foundation said on Saturday it was working with […]
            Do you like it?0
            Read more
            May 18, 2020
            Published by admin on May 18, 2020
            Categories
            • GBC Blog

            Fluxergy Announces $30 Million to Expand Manufacturing Capacity of Its One-hour Point-of-care Diagnostic Testing System in Response to COVID-19

            IRVINE, California, May 13, 2020 /PRNewswire/ — Irvine, California-based Fluxergy LLC, a diagnostic test company, is making a $30 million investment to expand its capability to scale production of the Fluxergy Analyzer […]
            Do you like it?0
            Read more
            May 8, 2020
            Published by admin on May 8, 2020
            Categories
            • GBC Blog

            FDA Grants Emergency Use Authorization for Rutgers’ At-Home COVID-19 Saliva Test

            Published: May 08, 2020 By Alex Keown Rutgers’ RUCDR Infinite Biologics received an amended Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) for the first SARS-CoV-2 coronavirus test that […]
            Do you like it?0
            Read more
            May 8, 2020
            Published by admin on May 8, 2020
            Categories
            • GBC Blog

            Profile of a Killer: The Complex Biology Powering the Coronavirus Pandemic

            Scientists are piecing together how SARS-CoV-2 operates, where it came from and what it might do next — but pressing questions remain about the source of […]
            Do you like it?0
            Read more
            April 23, 2020
            Published by admin on April 23, 2020
            Categories
            • GBC Blog

            Vela Diagnostics Coronavirus RT-PCR Test Provisionally Authorized by Singapore Regulator

            Vela Diagnostics said on Thursday it has received provisional authorization from Singapore’s Health Sciences Authority for the firm’s ViroKey SARS-CoV-2 RT-PCR Test. As a result, Vela […]
            Do you like it?0
            Read more
            April 21, 2020
            Published by admin on April 21, 2020
            Categories
            • In Vitro Diagnostics - IVD News

            OpGen Subsidiary Curetis GmbH and Karolinska Institute Collaborate in Study of Bacterial Co-Infections in COVID-19 Pneumonia Patients

            GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, April 21, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics […]
            Do you like it?0
            Read more
            April 16, 2020
            Published by admin on April 16, 2020
            Categories
            • In Vitro Diagnostics - IVD News

            OpGen Subsidiary Ares Genetics Demonstrates Feasibility and Potential of Next Generation Sequencing (NGS) Based Antibiotic Susceptibility Testing (AST) in Multi-Center Study

            VIENNA, Austria and GAITHERSBURG, Md., April 16, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics […]
            Do you like it?0
            Read more
            April 13, 2020
            Published by admin on April 13, 2020
            Categories
            • GBC Blog

            Bosch Develops Rapid Test To Combat Coronavirus Infections

            07-APR-2020. German engineering and technology company Bosch has said its rapid test can detect a SARS-CoV-2 coronavirus infection in patients within two-and-a-half hours. Developed in just […]
            Do you like it?0
            Read more
            Prev page
            1234567891011121314151617181920212223242526272829303132333435
            Next page

            Global BioClinical
            600 1st Avenue, Suite 330 PMB 80042
            Seattle, WA 98104-2246 USA

            Tel: +1 888 659 1221
            Fax: +1 206 299 9895
            Email: info@globalbioclinical.com

            Capabilities

            Trial Design and Management

            Data Management

            Regulatory and Quality

            Consulting and Program Management

            Biospecimens and Logistics

            Expertise

            Trial Types

            Health Innovation Solutions

            Clinical Applications

            About Us

            Company

            Management Team

            News & Events

            Contact

            © 2025 Global BioClinical. All rights reserved. | Privacy Policy

                      No results See all results
                      ✕